Is Arrowhead Pharmaceuticals Stock a Good Investment?
Arrowhead Pharmaceuticals Investment Advice | ARWR |
- Examine Arrowhead Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Arrowhead Pharmaceuticals' leadership team and their track record. Good management can help Arrowhead Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Arrowhead Pharmaceuticals' business and its evolving consumer preferences.
- Compare Arrowhead Pharmaceuticals' performance and market position to its competitors. Analyze how Arrowhead Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Arrowhead Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Arrowhead Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Arrowhead Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Arrowhead Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Arrowhead Pharmaceuticals Stock
Researching Arrowhead Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharmaceuticals recorded a loss per share of 5.78. The entity last dividend was issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011.
To determine if Arrowhead Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arrowhead Pharmaceuticals' research are outlined below:
| Arrowhead Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (609.69 M) with profit before overhead, payroll, taxes, and interest of 240.74 M. | |
| Arrowhead Pharmaceuticals currently holds about 416.5 M in cash with (462.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93. | |
| Arrowhead Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Insiders Sold US1.6m Of Arrowhead Pharmaceuticals Stock Possibly Sending Warning Sign |
Arrowhead Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arrowhead Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arrowhead Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Arrowhead Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Arrowhead Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-05 | 2019-12-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2018-02-09 | 2017-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2017-02-06 | 2016-12-31 | -0.2 | -0.17 | 0.03 | 15 | ||
2017-05-03 | 2017-03-31 | -0.12 | -0.08 | 0.04 | 33 | ||
2019-11-25 | 2019-09-30 | 0.16 | 0.11 | -0.05 | 31 | ||
2019-05-08 | 2019-03-31 | 0.19 | 0.24 | 0.05 | 26 | ||
2017-12-12 | 2017-09-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2016-08-09 | 2016-06-30 | -0.37 | -0.32 | 0.05 | 13 |
Know Arrowhead Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharmaceuticals backward and forwards among themselves. Arrowhead Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Arrowhead Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.2 M | Norges Bank | 2024-06-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Woodline Partners Lp | 2024-06-30 | 821.5 K | Western Financial Corp/ca | 2024-09-30 | 820.2 K | Blackrock Inc | 2024-06-30 | 15.7 M | Vanguard Group Inc | 2024-09-30 | 12.2 M |
Arrowhead Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.25 B.Market Cap |
|
Arrowhead Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (3.23) | (3.07) |
Determining Arrowhead Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Arrowhead Pharmaceuticals is a good buy. For example, gross profit margin measures Arrowhead Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arrowhead Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Arrowhead Pharmaceuticals' management efficiency
Arrowhead Pharmaceuticals has return on total asset (ROA) of (0.4072) % which means that it has lost $0.4072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5184) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.56. In addition to that, Return On Capital Employed is likely to drop to -0.61. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 11/28/2024, Non Current Assets Total is likely to grow to about 466.5 M, while Net Tangible Assets are likely to drop slightly above 202.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.60 | 1.67 | |
| Tangible Book Value Per Share | 1.52 | 1.60 | |
| Enterprise Value Over EBITDA | (4.16) | (4.37) | |
| Price Book Value Ratio | 12.51 | 13.14 | |
| Enterprise Value Multiple | (4.16) | (4.37) | |
| Price Fair Value | 12.51 | 13.14 | |
| Enterprise Value | 3.1 B | 3.3 B |
Effective management at Arrowhead Pharmaceuticals has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta 0.934 |
Basic technical analysis of Arrowhead Stock
As of the 28th of November, Arrowhead Pharmaceuticals shows the Mean Deviation of 2.71, risk adjusted performance of 0.0471, and Downside Deviation of 3.33. Arrowhead Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Arrowhead Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Arrowhead Pharmaceuticals is priced correctly, providing market reflects its regular price of 26.15 per share. Given that Arrowhead Pharmaceuticals has jensen alpha of 0.0492, we suggest you to validate Arrowhead Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Arrowhead Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arrowhead Pharmaceuticals' Outstanding Corporate Bonds
Arrowhead Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arrowhead Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arrowhead bonds can be classified according to their maturity, which is the date when Arrowhead Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Arrowhead Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Arrowhead Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0471 | |||
| Market Risk Adjusted Performance | 0.159 | |||
| Mean Deviation | 2.71 | |||
| Semi Deviation | 3.15 | |||
| Downside Deviation | 3.33 | |||
| Coefficient Of Variation | 1973.11 | |||
| Standard Deviation | 4.49 | |||
| Variance | 20.19 | |||
| Information Ratio | 0.0228 | |||
| Jensen Alpha | 0.0492 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.0307 | |||
| Treynor Ratio | 0.149 | |||
| Maximum Drawdown | 19.44 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 6.14 | |||
| Downside Variance | 11.11 | |||
| Semi Variance | 9.95 | |||
| Expected Short fall | (3.11) | |||
| Skewness | 2.29 | |||
| Kurtosis | 13.05 |
| Risk Adjusted Performance | 0.0471 | |||
| Market Risk Adjusted Performance | 0.159 | |||
| Mean Deviation | 2.71 | |||
| Semi Deviation | 3.15 | |||
| Downside Deviation | 3.33 | |||
| Coefficient Of Variation | 1973.11 | |||
| Standard Deviation | 4.49 | |||
| Variance | 20.19 | |||
| Information Ratio | 0.0228 | |||
| Jensen Alpha | 0.0492 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.0307 | |||
| Treynor Ratio | 0.149 | |||
| Maximum Drawdown | 19.44 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 6.14 | |||
| Downside Variance | 11.11 | |||
| Semi Variance | 9.95 | |||
| Expected Short fall | (3.11) | |||
| Skewness | 2.29 | |||
| Kurtosis | 13.05 |
Consider Arrowhead Pharmaceuticals' intraday indicators
Arrowhead Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arrowhead Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Arrowhead Pharmaceuticals Corporate Filings
10K | 26th of November 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F5 | 15th of November 2024 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 16th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Arrowhead Stock media impact
Far too much social signal, news, headlines, and media speculation about Arrowhead Pharmaceuticals that are available to investors today. That information is available publicly through Arrowhead media outlets and privately through word of mouth or via Arrowhead internal channels. However, regardless of the origin, that massive amount of Arrowhead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arrowhead Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arrowhead Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arrowhead Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arrowhead Pharmaceuticals alpha.
Arrowhead Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Arrowhead Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Arrowhead Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Kenneth Myszkowski | Chief Officer | Profile | |
| Javier MD | Chief Officer | Profile | |
| Bruce MD | Chief Scientist | Profile | |
| Vincent CFA | Head VP | Profile | |
| MBA MD | Chief Medicine | Profile | |
| Tracie Oliver | Chief Officer | Profile |
Already Invested in Arrowhead Pharmaceuticals?
The danger of trading Arrowhead Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arrowhead Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arrowhead Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arrowhead Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.